Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma

Hepatology Research

Volumn 43, Issue 7, 2013, Pages 757-764

  Limaye, Alpna R ^a   Clark, Virginia ^a   Soldevila Pico, Consuelo ^a   Morelli, Giuseppe ^a   Suman, Amitabh ^a   Firpi, Roberto ^a   Nelson, David R ^a   Cabrera, Roniel ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Neutrophil lymphocyte ratio

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84879717994     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12019     Document Type: Article

References (25)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139 (10): 817-823.
2. Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol 2008; 43: 18-26.
3. Ringe B, Picklmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270-285.
4. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 1993; 218: 145-151.
5. Iwatsuki S, Starzl TE, Sheahan DG etal. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214 (3): 221-228.
6. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11): 693-699.
7. Zimmerman MA, Ghobrial RM, Tong MJ etal. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143 (2): 182-188.
8. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007; 73: 215-220.
9. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428.
10. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16: 614-622.
11. Halazun KJ, Hardy MA, Rana AA etal. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250 (1): 141-151.
12. Bertuzzo VR, Cescon M, Ravaioli M etal. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation 2011; 91 (11): 1279-1285.
13. Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011; 22 (5): 702-709.
14. Liang W, Wang D, Ling X etal. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18 (1): 62-69.
15. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet 2001; 357 (9255): 539-545.
16. Hashimoto K, Ikeda Y, Korenaga D etal. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103 (9): 1856-1864.
17. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27 (2): 407-414.
18. Cao M, Cabrera R, Xu Y etal. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+) CD25 (+) regulatory T cells. Lab Invest 2007; 87 (6): 582-590.
19. Cabrera R, Ararat M, Eksioglu EA etal. Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma. Scand J Immunol 2010; 72 (4): 293-301.
20. Cheng JW, Shi YH, Fan J etal. An immune function assay predicts post-transplant recurrence in patient with hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137 (10): 1445-1453.
21. Tavares-Murta BM, Mendonca MA, Duarte NL etal. Systemic leukocyte alterations are associated with invasive uterine cancer. Int J Gynecol Cancer 2010; 20 (7): 1154-1159.
22. Gong Y, Koh DR. Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. Cell Tissue Res 2010; 339 (2): 437-448.
23. Bergers G, Brekken R, McMahon G etal. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2 (10): 747-44.
24. Kuang DM, Zhao Q, Wu Y etal. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54 (5): 948-955.
25. Wee A. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology 2011; 22 (5): 287-305.